MedTrace Logo

Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes

NCT00729898 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 243

Last updated 2016-10-31

No results posted yet for this study

Summary

This study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in patients with type 2 diabetes during NovoMix® 30 treatment.

Conditions

Interventions

DRUG

biphasic insulin aspart 30

Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2010-09-30
Completion
2010-09-30

Countries

  • Norway
  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00729898 on ClinicalTrials.gov